Abstract: The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment.

Abstract: The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment.

Abstract: The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment.

Abstract: The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment.

Abstract: A recombinant Na+, K+-ATPase ?1-subunit protein resistant to cardiac glycosides, e.g. oubain, is disclosed, as well as methods for its production and use. The resistance to cardiac glycosides are obtained by alterations in the region situated between and including the amino acids 65-133. Such recombinant protein and nucleic acid constructs expressing the same are useful as selection markers in gene therapy and research applications.

Abstract: A recombinant Na+, K+-ATPase ?1-subunit protein resistant to cardiac glycosides, e.g. oubain, is disclosed, as well as methods for its production and use. The resistance to cardiac glycosides are obtained by alterations in the region situated between and including the amino acids 65-133. Such recombinant protein and nucleic acid constructs expressing the same are useful as selection markers in gene therapy and research applications.

Abstract: An isolated cell having a nucleic acid construct encoding a recombinant Na+, K+-ATPase ?1-subunit protein resistant to cardiac glycosides, e.g., ouabain, is disclosed. Selected amino acid substitutions in the normal human Na+, K+-ATPase ?1-subunit confers resistance to cardiac glycosides. Cardiac glycoside resistant Na+, K+-ATPase ?1-subunits may be useful as selection markers in gene therapy and research applications.

Abstract: The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment.

Abstract: A recombinant Na+, K+-ATPase ?1-subunit protein resistant to cardiac gIycosides, e.g. oubain, is disclosed, as well as methods for its production and use. The resistance to cardiac glycosides are obtained b y alterations in the region situated between and including the amino acids 65-133. Such recombinant protein and nucleic acid constructs expressing the same are useful as selection markers in gene therapy and research applications.

Abstract: Mammalian cells, normally dependent of IL-2, can be successfully transfected to express IL-2 in amounts sufficient to sustain growth without the external addition of IL-2. One cell line expressing IL-2 solely in the endoplasmatic reticulum without secretion, and one cell line capable of secretion of IL-2 have been developed and tested. Preliminary experiments using primary cells from human donors confirm the feasibility of the invention. The invention makes available gene-modified cells, methods for their production, as well as methods of the treatment of cancer and for immunostimulation.

Abstract: The invention refers to a medium for expanding natural killer cells expressing the CD56+CD3− phenotype, comprising CellGro® SCGM to which has been added interleukin-2, anti CD3 antibodies, and optionally serum, as well as a method of expanding said natural killer cells, isolated from a mononuclear cell concentrate, by suspension and incubation in said medium. The expanded NK cells can be used for curative or prophylactic treatment of patients, especially cancer patients undergoing stem cell transplantation.